9月15日，Monte Rosa盘前暴涨55%，公司与诺华制药达成57亿美元授权合作协议。
诺华制药与药物研发公司Monte Rosa Therapeutics签署了一项价值高达57亿美元的授权合作协议，以共同开发用于免疫介导疾病的药物。
根据协议，Monte Rosa将获得1.2亿美元的预付款，并有机会通过里程碑付款和销售分成获得额外收益，使交易总额最高达到57亿美元。
9月15日，Monte Rosa盘前暴涨55%，公司与诺华制药达成57亿美元授权合作协议。
诺华制药与药物研发公司Monte Rosa Therapeutics签署了一项价值高达57亿美元的授权合作协议，以共同开发用于免疫介导疾病的药物。
根据协议，Monte Rosa将获得1.2亿美元的预付款，并有机会通过里程碑付款和销售分成获得额外收益，使交易总额最高达到57亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.